Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group

Nat Med. 2021 Apr;27(4):569-570. doi: 10.1038/s41591-021-01299-5.

Authors

Jerome Amir Singh^{1

2}, Sonali Kochhar^{3

4}, Jonathan Wolff⁵; WHO ACT-Accelerator Ethics & Governance Working Group

Collaborators

WHO ACT-Accelerator Ethics & Governance Working Group:
Caesar Atuire, Anant Bhan, Ezekiel Emanuel, Ruth Faden, Prakash Ghimire, Dirceu Greco, Calvin Ho, Suerie Moon, Ehsan Shamsi-Gooshki, Aissatou Touré, Beatriz Thomé, Maxwell J Smith, Ross E G Upshur

Affiliations

¹ Howard College School of Law, University of KwaZulu-Natal, Durban, South Africa. singhj9@ukzn.ac.za.
² Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. singhj9@ukzn.ac.za.
³ Department of Global Health, University of Washington, Seattle, WA, USA.
⁴ Global Healthcare Consulting, Delhi, India.
⁵ Blavatnik School of Government, University of Oxford, Oxford, UK.

PMID: 33727699
DOI: 10.1038/s41591-021-01299-5

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Clinical Trials as Topic*
Humans
Placebo Effect
SARS-CoV-2 / immunology*
World Health Organization

Substances

COVID-19 Vaccines